Second-Line, Biomarker-Driven Therapies for Squamous NSCLC: Report on Lung-MAP SWOG S1400

China’s Domestic PD-1/PD-L1 Inhibitors Demanding Global Attention

Biomarkers May Illuminate the Path Forward for PARP Inhibitors in SCLC

IASLC Studying Impact of COVID-19 on International Lung Cancer Clinical Trial Enrollment, Mitigation Strategies

NCI Launches the Cancer Moonshot SM Biobank to Accelerate Research in Cancer Treatment

Voice from Asia: Combination of Immune Checkpoint Inhibitors With Chemotherapy for Advanced Non-squamous NSCLC

ASCO and Ontario Health Publish Joint Guideline Update on Systemic Therapy for Stage IV NSCLC

Immunotherapy Use in Patients With Lung Cancer and Comorbidities

Cancer Clinical Trial Compensation: Undue or Long Overdue?

Increasing Understanding about the Role Biosimilar Agents Play in Everyday Practice: A Q&A with Dr. Gary Lyman (Part 2 of 2)

Ensuring Quality of Life During Lung Cancer Survivorship Requires a Multidisciplinary Team

COVID-19 and Lung Cancer: A Call for Immediate Action